Maxalt and Arteriospasm coronary - a phase IV clinical study of FDA data

Summary:

Arteriospasm coronary is reported as a side effect among people who take Maxalt (rizatriptan benzoate), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Metronidazole, and have Attention deficit hyperactivity disorder.

The phase IV clinical study analyzes which people have Arteriospasm coronary when taking Maxalt. It is created by eHealthMe based on reports of 11,566 people who have side effects when taking Maxalt from the FDA, and is updated regularly.

What is Maxalt?

Maxalt has active ingredients of rizatriptan benzoate. It is often used in migraine. eHealthMe is studying from 12,754 Maxalt users. Check the latest studies of Maxalt.

What is Arteriospasm coronary?

Arteriospasm coronary (spasm of the large- or medium-sized coronary arteries) is found to be associated with 340 drugs and 498 conditions by eHealthMe. Check the latest studies of Arteriospasm coronary.

On Jul, 10, 2026

11,566 people reported to have side effects when taking Maxalt.
Among them, 20 people (0.17%) have Arteriospasm coronary.

Could Maxalt cause Arteriospasm coronary?

Among these 20 people:

How long have people been on Maxalt when they have Arteriospasm coronary? *

What is the gender of people who have Arteriospasm coronary when taking Maxalt? *

female: 78.95 %
male: 21.05 %

What is the age of people who have Arteriospasm coronary when taking Maxalt? *

What are other drugs people take besides Maxalt? *

Wellbutrin: 4 people, 20.00%
Metronidazole: 4 people, 20.00%
Ceftriaxone: 3 people, 15.00%
Vancomycin Hydrochloride: 3 people, 15.00%
Methylphenidate: 3 people, 15.00%
Fosamax: 3 people, 15.00%
Piperacillin And Tazobactam: 2 people, 10.00%
Oracea: 2 people, 10.00%
Aimovig: 2 people, 10.00%
Amlodipine: 2 people, 10.00%

What are other side effects people have besides Arteriospasm coronary? *

Heart Attack: 9 people, 45.00%
Acute Myocardial Infarction (acute heart attack): 4 people, 20.00%
Kounis Syndrome (the concurrence of heart pain with conditions associated with mast cell activation leads to heart muscle damage): 4 people, 20.00%
Drug Hypersensitivity: 4 people, 20.00%
Stable Angina (a constant chest pain): 4 people, 20.00%
Drug Ineffective: 4 people, 20.00%
Chest Pain: 3 people, 15.00%
Hypersensitivity: 3 people, 15.00%
Hypokinesia (decreased bodily movement): 3 people, 15.00%
Headache (pain in head): 3 people, 15.00%

What are the existing conditions these people have? *

Groin Abscess (pus in groin): 4 people, 20.00%
Cellulitis (infection under the skin): 4 people, 20.00%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 4 people, 20.00%
Depression: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Maxalt and have Arteriospasm coronary?

- Check whether Arteriospasm coronary is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Maxalt:

Maxalt (12,754 reports)

Browse all side effects of Maxalt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Arteriospasm coronary:

Arteriospasm coronary (340 drugs)

Browse all the conditions that are associated with Arteriospasm coronary:

Arteriospasm coronary (498 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rizatriptan benzoate (the active ingredients of Maxalt) and Maxalt (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.